FGFR1 and non-small cell lung carcinoma: On the other hand, two FGFR1-amplified NSCLC PDX (from large cell and adenocarcinoma subtypes) with co-overexpression of FGFR1 protein responded to M6123 (selective FGFR1 antagonist) (26).